Antibody-drug conjugates consist of an antibody attached to a chemotherapy drug that delivers chemotherapy only where it is needed, limiting unwanted side effects. ADCs work by combining the ability of antibodies to target cancer cells with the ability of chemotherapy drugs to kill cancer cells.
Three ADCs are approved for MBC: ado-trastuzumab emtansine (Kadcyla®) for HER2+ MBC, fam-trastuzumab deruxtecan (Enhertu®) for HER2+ MBC, and sacituzumab govitecan-hziy (Trodelvy®) for triple-negative MBC. Others are being tested in clinical trials.
Read below for general information about how ADCs work, a recent comparison of the two ADCs for HER2+ MBC, and news about sacituzumab govitecan-hziy (Trodelvy®), the recently approved ADC for triple-negative MBC.
General Information About ADCs
- Roche (Video): What Are Antibody-Drug Conjugates And How Do They Work Against Cancer?
- Susan G. Komen: Emerging Areas In Metastatic Breast Cancer Treatment
ADCs For HER2+ MBC
- Targeted Oncology: Trastuzumab Deruxtecan Shows Efficacy Over T-DM1 In HER2+ Breast Cancer
- OncLive: ADC Treatment Options And Clinical Data In Breast Cancer
- Targeted Oncology: Trastuzumab Deruxtecan For HER2-Low Breast Cancer
ADC For Triple-Negative MBC
- FDA: FDA Approval Of Sacituzumab Govitecan For Triple-Negative MBC
- National Cancer Institute: Sacituzumab Granted Regular FDA Approval For TNBC
Clinical Trials That Include Antibody-Drug Conjugates
- Metastatic Trial Search: MBC Trials That Include Antibody-Drug Conjugates
- Solid Tumor Trials: Trials That May Include Antibody-Drug Conjugates
Last Modified on March 10, 2022